Rapid Change in the Use of Antiretroviral Agents and Improvement in a Population of HIV-Infected Patients: France, 1995 to 1997
Authors:
- Rosemary SpiraRSRosemary Spira
- Catherine MarimoutouCMCatherine Marimoutou
- Christine BinquetCBChristine Binquet
- Denis LacosteDLDenis Lacoste
- François DabisFDFrançois Dabis
- 1 August 1998
- journal article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 18 (4) , 358-364
Abstract
To describe the recent evolution of antiretroviral prescriptions and to look for clinical and biological changes among a population of HIV-infected patients. Patients received follow-up in the hospital-based information system of the Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA), Southwestern France, from 1995 to 1997. Quarterly evolution of the prescriptions of antiretroviral treatments and of the population clinical and biological indicators were studied in this observational survey of computerized records obtained after each hospital contact. Overall numbers of patients who received follow-up and of hospital contacts remained stable. The proportion of untreated patients decreased from 38.5% to 10.5%. Monotherapies were progressively abandoned. Double combination therapies with two nucleoside analogues were used for 55% of the patients by early 1996 and then decreased, whereas triple combination therapies with one protease inhibitor (PI) rapidly increased to comprise up to 40% of the prescriptions in 1997. PIs were prescribed earlier and earlier in the course of HIV infection. Overall incidence of AIDS diagnoses and mortality rate decreased by 18% and 22%, respectively, in the first 9 months of use of PIs compared with the preceding 9 months, and by 47% and 56%, respectively, in the following 9 months (p<.001). The number of hospitalizations and the proportion of patients with a CD4 cell count <200/mm3 decreased. AIDS cases diagnosed after introduction of PIs had rarely been treated with PIs. Over this 3-year period, physicians prescribed antiretroviral treatments more and more frequently, and triple combination therapy with PI is now common practice in France. Patients clinical and biological patterns have improved 18 months after the introduction of PIs.Keywords
This publication has 11 references indexed in Scilit:
- Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centresAIDS, 1997
- A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or LessNew England Journal of Medicine, 1997
- Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel1997
- Impact of Combination Therapy for HIV Infection on Inpatient CensusNew England Journal of Medicine, 1997
- Decline in deaths from AIDS due to new antiretroviralsThe Lancet, 1997
- British HIV Association guidelines for antiretroviral treatment of HIV seropositive individualsThe Lancet, 1997
- Reductions in HIV-1 disease progression for zidovudine/lamivudine relative to control treatmentsAIDS, 1997
- A Trial Comparing Nucleoside Monotherapy with Combination Therapy in HIV-Infected Adults with CD4 Cell Counts from 200 to 500 per Cubic MillimeterNew England Journal of Medicine, 1996
- Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individualsThe Lancet, 1996
- Hospital-based surveillance and emerging patterns of HIV transmissionAIDS, 1996